Download PDF
Semin Reprod Med 2006; 24(1): 033-039
DOI: 10.1055/s-2006-931799
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Endocrinology of Recurrent Pregnancy Loss

Francisco Arredondo1 , Luis S. Noble2
  • 1Assistant Professor, Division of Reproductive Endocrinology and Infertility Case Western Reserve University, Cleveland Ohio
  • 2Associate Clinical Professor, Department of Obstetrics and Gynecology, Texas Tech University Medical Center, and Medical Director of Southwest Center for Reproductive Health, El Paso, Texas
Further Information

Publication History

Publication Date:
18 January 2006 (online)

    Permissions and Reprints

ABSTRACT

Following implantation, the maintenance of the pregnancy is dependent on a multitude of endocrinological events that will eventually aid in the successful growth and development of the fetus. Although the great majority of pregnant women have no pre-existing endocrine abnormalities, a small number of women can have certain endocrine alterations that could potentially lead to recurrent pregnancy losses. It is estimated that approximately 8 to 12% of all pregnancy losses are the result of endocrine factors. During the preimplantation period, the uterus undergoes important developmental changes stimulated by estrogen, and more importantly, progesterone. Progesterone is essential for the successful implantation and maintenance of pregnancy. Therefore, disorders related to inadequate progesterone secretion by the corpus luteum are likely to affect the outcome of the pregnancy. Luteal phase deficiency, hyperprolactinemia, and polycystic ovarian syndrome are some examples. Several other endocrinological abnormalities such as thyroid disease, hypoparathyroidism, uncontrolled diabetes, and decreased ovarian reserve have been implicated as etiologic factors for recurrent pregnancy loss.

KEYWORDS

Recurrent pregnancy loss - endocrine factors - prolactin - thyroid - luteal phase - ovarian reserve

REFERENCES

  • 1 Szlachter N, O'Byrne E, Goldsmith L et al.. Myometrial inhibiting activity of relaxin containing extracts of human corpora lutea of pregnancy.  Am J Obstet Gynecol. 1980;  136 584-586
    PubMedGoogle Scholar
  • 2 Bigazzi M, Nardi E. Prolactin and relaxin: antagonism on the spontaneous motility of the uterus.  J Clin Endocrinol Metab. 1981;  53 665
    PubMedGoogle Scholar
  • 3 Csapo A L, Pulkkinen M O, Wiest W G. Effects of lutectomy and progesterone replacement in early pregnant patients.  Am J Obstet Gynecol. 1973;  115 759-764
    PubMedGoogle Scholar
  • 4 Insler V. Corpus luteum defects.  Curr Opin Obstet Gynecol. 1992;  4(2) 203-211
    PubMedGoogle Scholar
  • 5 Tuckerman E, Laird S M, Stewart R, Wells M, Li T C. Markers of endometrial function in women with unexplained recurrent pregnancy loss.  Hum Reprod. 2004;  19(1) 196-205
    PubMedGoogle Scholar
  • 6 Jacobs M H, Balasch J, Gonzalez-Merlo J M. Endometrial cytosolic and nuclear progesterone receptors in the luteal phase defect.  J Clin Endocrinol Metab. 1987;  64 472-478
    PubMedGoogle Scholar
  • 7 Rosenfeld D L, Garcia C R. A comparison of endometrial histology with simultaneous plasma progesterone determinations in infertile women.  Fertil Steril. 1976;  27 1256
    PubMedGoogle Scholar
  • 8 Koninckx P R, Goddeeries P G, Lauweryns J M, de Hertogh R C, Brosens I A. Accuracy of endometrial biopsy dating in relation to the mid-cycle luteinizing hormone peak.  Fertil Steril. 1977;  28 443-445
    PubMedGoogle Scholar
  • 9 Hensleigh P A, Fainstat T. Corpus luteum dysfunction: serum progesterone levels in the diagnosis and assessment of therapy for recurrent and threatened abortion.  Fertil Steril. 1979;  32 396
    PubMedGoogle Scholar
  • 10 Cumming D C, Honore L H, Scott J Z, Williams K P. The late luteal phase in infertile women: comparison of simultaneous endometrial biopsy and progesterone levels.  Fertil Steril. 1985;  43(5) 715-719
    PubMedGoogle Scholar
  • 11 Noyes R W. Uniformity of secretory endometriosis.  Obstet Gynecol. 1956;  7 221
    PubMedGoogle Scholar
  • 12 Coutifaris C, Myers E R, Guzick D S and NICHD National Cooperative Reproductive Medicine Network et al. Histological dating of timed endometrial biopsy tissue is not related to fertility status.  Fertil Steril. 2004;  82(5) 1264-1272
    CrossrefPubMedGoogle Scholar
  • 13 Phung Thi Tho, Byrd J R, McDonough P G. Etiologies and subsequent reproductive performance in 100 couples with recurrent abortion.  Fertil Steril. 1979;  32 389-395
    PubMedGoogle Scholar
  • 14 Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage: a meta-analysis of controlled trials.  Br J Obstet Gynaecol. 1989;  96 275
    PubMedGoogle Scholar
  • 15 Mills J L, Simpson J L, Driscoll S et al.. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception.  N Engl J Med. 1988;  319 1617-1621
    CrossrefPubMedGoogle Scholar
  • 16 Karamardian L M, Grimes D A. Luteal phase deficiency: effect of treatment on pregnancy rates.  Am J Obstet Gynecol. 1992;  167(5) 1391-1398
    PubMedGoogle Scholar
  • 17 del Pozo E, Wyss H, Tolis G, Alcaniz J, Campana A, Naflolin F. Prolactin and deficient luteal function.  Obstet Gynecol. 1979;  53 282-286
    PubMedGoogle Scholar
  • 18 Roberts C P, Murphy A A. Endocrinopathies associated with recurrent pregnancy loss.  Semin Reprod Med. 2000;  18(4) 357-362
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Byrne J L, Ward K. Genetic factors in recurrent abortion.  Clin Obstet Gynecol. 1994;  37(3) 693-704
    PubMedGoogle Scholar
  • 20 Dorrington J, Gore-Langton R E. Prolactin inhibits oestrogen synthesis in the ovary.  Nature. 1981;  290 600
    CrossrefPubMedGoogle Scholar
  • 21 Magoffin D A, Erickson G F. Prolactin inhibition of luteinizing hormone-stimulated androgen synthesis in ovarian interstitial cells cultured in defined medium: mechanisms of action.  Endocrinology. 1982;  111 2001-2007
    PubMedGoogle Scholar
  • 22 McNatty K P, Sawers R S. Relationship between the endocrine environment within the graafian follicle and the subsequent secretion of progesterone by human granulosa cells in culture.  J Endocrinol. 1975;  66 391-400
    PubMedGoogle Scholar
  • 23 Hirahara F, Andoh N, Sawai K, Hirabuki T, Uemura T, Minaguchi H. Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials.  Fertil Steril. 1998;  70(2) 246-252
    CrossrefPubMedGoogle Scholar
  • 24 Goldsmith R E, Sturgis S H, Lerman J, Stanbury J B. The menstrual pattern in thyroid disease.  J Clin Endocrinol Metab. 1952;  12(7) 846-855
    PubMedGoogle Scholar
  • 25 Davis L E, Lucas M J, Hankins G D, Roark M L, Cunningham F G. Thyrotoxicosis complicating pregnancy.  Am J Obstet Gynecol. 1989;  160 63-70
    CrossrefPubMedGoogle Scholar
  • 26 Kriplani A, Buckshee K, Bhargava V L, Takkar D, Ammini A C. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy.  Eur J Obstet Gynecol Reprod Biol. 1994;  54(3) 159-163
    CrossrefPubMedGoogle Scholar
  • 27 Daniels G H. Thyroid disease and pregnancy: a clinical overview.  Endocr Pract. 1995;  1 287-301
    PubMedGoogle Scholar
  • 28 Nakayama T, Yamamoto T, Kanmatsuse K, Kokubun S. Graves' disease associated with anticardiolipin antibody positivity and acquired protein S deficiency.  Rheumatol Int. 2003;  23(4) 198-200
    CrossrefPubMedGoogle Scholar
  • 29 Anselmo J, Cao D, Karrison T, Weiss R E, Refetoff S. Fetal loss associated with excess thyroid hormone exposure.  JAMA. 2004;  292(6) 691-695
    CrossrefPubMedGoogle Scholar
  • 30 Wakim A N, Polizotto S L, Buffo M J, Marrero M A, Burholt D R. Thyroid hormones in human follicular fluid and thyroid hormone receptors in human granulosa cells.  Fertil Steril. 1993;  59(6) 1187-1190
    PubMedGoogle Scholar
  • 31 Steinberger E, Nader S, Rodriguez-Rigau L, Ayala C, Smith K. Prolactin response to thyrotropin-releasing hormone in normoprolactinemic patients with ovulatory dysfunction and its use for selection of candidates for bromocriptine therapy.  J Endocrinol Invest. 1990;  13(8) 637-642
    PubMedGoogle Scholar
  • 32 Del Pozo E, Wyss H, Tolis G et al.. Prolactin and deficient luteal function.  Obstet Gynecol. 1979;  53 282-286
    PubMedGoogle Scholar
  • 33 Davis L E, Leveno K J, Cunningham F G. Hypothyroidism complicating pregnancy.  Obstet Gynecol. 1988;  72(1) 108-112
    PubMedGoogle Scholar
  • 34 Casey B M, Dashe J S, Wells C E et al.. Subclinical hypothyroidism and pregnancy outcomes.  Obstet Gynecol. 2005;  105(2) 239-245
    CrossrefPubMedGoogle Scholar
  • 35 Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion.  Am J Obstet Gynecol. 1984;  148(2) 140-146
    CrossrefPubMedGoogle Scholar
  • 36 Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases.  Hum Reprod. 1994;  9(7) 1328-1332
    PubMedGoogle Scholar
  • 37 Bohnet H G, Fiedler K, Leidenberger F A. Subclinical hypothyroidism and infertility.  Lancet. 1981;  2(8258) 1278
    PubMedGoogle Scholar
  • 38 Daya S, Ward S, Burrows E. Progesterone profiles in luteal phase defect cycles and outcome of progesterone treatment in patients with recurrent spontaneous abortion.  Am J Obstet Gynecol. 1988;  158(2) 225-232
    PubMedGoogle Scholar
  • 39 Coutifaris C, Myers E R, Guzick D S et al.. NICHD National Cooperative Reproductive Medicine Network. Histological dating of timed endometrial biopsy tissue is not related to fertility status.  Fertil Steril. 2004;  82(5) 1264-1272
    CrossrefPubMedGoogle Scholar
  • 40 Kazer R R. Endometrial biopsy should be abandoned as a routine component of the infertility evaluation.  Fertil Steril. 2004;  82(5) 1297-1298 (discussion 1300-1302)
    CrossrefPubMedGoogle Scholar
  • 41 Regan L, Rai R. Epidemiology and the medical causes of miscarriage.  Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;  14(5) 839-854
    CrossrefPubMedGoogle Scholar
  • 42 Oates-Whitehead R M, Haas D M, Carrier J A. Progestogen for preventing miscarriage.  Cochrane Database Syst Rev. 2003;  (4) CD003511
    PubMedGoogle Scholar
  • 43 Baloch Z, Carayon P, Conte-Devolx B Guidelines Committee, National Academy of Clinical Biochemistry et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.  Thyroid. 2003;  13(1) 3-126
    CrossrefPubMedGoogle Scholar
  • 44 Weetman A P. Autoimmune thyroid disease.  Autoimmunity. 2004;  37(4) 337-340
    CrossrefPubMedGoogle Scholar
  • 45 Kutteh W H, Yetman D L, Carr A C, Beck L A, Scott Jr R T. Increased prevalence of antithyroid antibodies identified in women with recurrent pregnancy loss but not in women undergoing assisted reproduction.  Fertil Steril. 1999;  71(5) 843-848
    CrossrefPubMedGoogle Scholar
  • 46 Rushworth F H, Backos M, Rai R, Chilcott I T, Baxter N, Regan L. Prospective pregnancy outcome in untreated recurrent miscarriers with thyroid autoantibodies.  Hum Reprod. 2000;  15(7) 1637-1639
    CrossrefPubMedGoogle Scholar
  • 47 Magaro M, Zoli A, Altomonte L et al.. The association of silent thyroiditis with active systemic lupus erythematosus.  Clin Exp Rheumatol. 1992;  10(1) 67-70
    PubMedGoogle Scholar
  • 48 Santoro N. Research on the mechanisms of premature ovarian failure.  J Soc Gynecol Investig. 2001;  8(1 suppl) S10-S12
    PubMedGoogle Scholar
  • 49 Hak A E, Pols H A, Visser T J, Drexhage H A, Hofman A, Witteman J C. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.  Ann Intern Med. 2000;  132(4) 270-278
    PubMedGoogle Scholar
  • 50 Stewart-Akers A M, Krasnow J S, Brekosky J, DeLoia J A. Endometrial leukocytes are altered numerically and functionally in women with implantation defects.  Am J Reprod Immunol. 1998;  39(1) 1-11
    PubMedGoogle Scholar
  • 51 Matalon S T, Blank M, Ornoy A et al.. The association between anti-thyroid antibodies and pregnancy loss.  Am J Reprod Immunol. 2001;  45(2) 72-77
    PubMedGoogle Scholar
  • 52 Christiansen O B, Nybo Andersen A M, Bosch E et al.. Evidence-based investigations and treatments of recurrent pregnancy loss.  Fertil Steril. 2005;  83(4) 821-839
    CrossrefPubMedGoogle Scholar
  • 53 Mills J L, Simpson J L, Driscoll S G et al.. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception.  N Engl J Med. 1988;  319(25) 1617-1623
    CrossrefPubMedGoogle Scholar
  • 54 Greene M F, Hare J W, Cloherty J P, Benacerraf B R, Soeldner J S. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy.  Teratology. 1989;  39(3) 225-231
    CrossrefPubMedGoogle Scholar
  • 55 Ray J G, O'Brien T E, Chan W S. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis.  QJM. 2001;  94(8) 435-444
    CrossrefPubMedGoogle Scholar
  • 56 Kitzmiller J L, Watt N, Driscoll S G. Decidual arteriopathy in hypertension and diabetes in pregnancy: immunofluorescent studies.  Am J Obstet Gynecol. 1981;  141(7) 773-779
    PubMedGoogle Scholar
  • 57 Lea R G, McCracken J E, McIntyre S S et al.. Disturbed development of the preimplantation embryo in the insulin-dependent diabetic BB/E rat.  Diabetes. 1996;  45(11) 1463-1470
    PubMedGoogle Scholar
  • 58 Keim A L, Chi M M, Moley K H. Hyperglycemia-induced apoptotic cell death in the mouse blastocyst is dependent on expression of p53.  Mol Reprod Dev. 2001;  60(2) 214-224
    CrossrefPubMedGoogle Scholar
  • 59 Moley K H, Chi M M, Mueckler M M. Maternal hyperglycemia alters glucose transport and utilization in mouse preimplantation embryos.  Am J Physiol. 1998;  275(1 pt 1) E38-E47
    PubMedGoogle Scholar
  • 60 Wyse L J, Jones M, Mandel F. Relationship of glycosylated hemoglobin, fetal macrosomia, and birthweight macrosomia.  Am J Perinatol. 1994;  11(4) 260-262
    PubMedGoogle Scholar
  • 61 Temple R, Aldridge V, Greenwood R et al.. Association between outcome of pregnancy and glycaemic control in early pregnancy in type 1 diabetes: population based study.  BMJ. 2002;  325(7375) 1275-1276
    CrossrefPubMedGoogle Scholar
  • 62 Nielsen G L, Sorensen H T, Nielsen P H et al.. Glycosylated hemoglobin as predictor of adverse fetal outcome in type 1 diabetic pregnancies.  Acta Diabetol. 1997;  34(3) 217-222
    CrossrefPubMedGoogle Scholar
  • 63 Glueck C J, Wang P, Goldenberg N et al.. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.  Hum Reprod. 2002;  17(11) 2858-2864
    CrossrefPubMedGoogle Scholar
  • 64 Sagle M, Bishop K, Ridley N et al.. Recurrent early miscarriage and polycystic ovaries.  BMJ. 1988;  297(6655) 1027-1028
    PubMedGoogle Scholar
  • 65 Glueck C J, Wang P, Fontaine R N et al.. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.  Metabolism. 1999;  48(12) 1589-1595
    CrossrefPubMedGoogle Scholar
  • 66 Glueck C J, Phillips H, Cameron D et al.. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.  Fertil Steril. 2001;  75(1) 46-52
    CrossrefPubMedGoogle Scholar
  • 67 Velazquez E M, Mendoza S G, Wang P et al.. Metformin therapy is lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.  Metabolism. 1997;  46(4) 454-457
    CrossrefPubMedGoogle Scholar
  • 68 Wang J X, Davies M J, Norman R J. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment.  Hum Reprod. 2001;  16(12) 2606-2609
    CrossrefPubMedGoogle Scholar
  • 69 Okon M A, Laird S M, Tuckerman E M et al.. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function.  Fertil Steril. 1998;  69(4) 682-690
    CrossrefPubMedGoogle Scholar
  • 70 Tuckerman E M, Okon M A, Li T et al.. Do androgens have a direct effect on endometrial function? An in vitro study.  Fertil Steril. 2000;  74(4) 771-779
    CrossrefPubMedGoogle Scholar
  • 71 Regan L, Owen E J, Jacobs H S. Hypersecretion of luteinising hormone, infertility, and miscarriage.  Lancet. 1990;  336(8724) 1141-1144
    CrossrefPubMedGoogle Scholar
  • 72 Watson H, Kiddy D S, Hamilton-Fairley D et al.. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage.  Hum Reprod. 1993;  8(6) 829-833
    PubMedGoogle Scholar
  • 73 Nardo L G, Rai R, Backos M et al.. High serum luteinizing hormone and testosterone concentrations do not predict pregnancy outcome in women with recurrent miscarriage.  Fertil Steril. 2002;  77(2) 348-352
    CrossrefPubMedGoogle Scholar
  • 74 Westergaard L G, Laursen S B, Andersen C Y. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction.  Hum Reprod. 2000;  15(5) 1003-1008
    CrossrefPubMedGoogle Scholar
  • 75 Clifford K, Rai R, Watson H et al.. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial.  BMJ. 1996;  312(7045) 1508-1511
    PubMedGoogle Scholar
  • 76 Craig L B, Ke R W, Kutteh W H. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss.  Fertil Steril. 2002;  78 487-490
    CrossrefPubMedGoogle Scholar
  • 77 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.  Fertil Steril. 2004;  81(1) 19-25
    PubMedGoogle Scholar
  • 78 Jakubowicz D J, Iuorno M J, Jakubowicz S et al.. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2002;  87(2) 524-529
    CrossrefPubMedGoogle Scholar
  • 79 Stadtmauer L A, Wong B C, Oehninger S. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome-beyond ovulation induction.  Hum Reprod. 2002;  17(12) 3016-3026
    CrossrefPubMedGoogle Scholar
  • 80 Trout S W, Seifer D B. Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values?.  Fertil Steril. 2000;  74(2) 335-337
    CrossrefPubMedGoogle Scholar
  • 81 Gurbuz B, Yalti S, Ozden S et al.. High basal estradiol level and FSH/LH ratio in unexplained recurrent pregnancy loss.  Arch Gynecol Obstet. 2004;  270(1) 37-39
    PubMedGoogle Scholar
  • 82 Hofmann G E, Khoury J, Thie J. Recurrent pregnancy loss and diminished ovarian reserve.  Fertil Steril. 2000;  74(6) 1192-1195
    CrossrefPubMedGoogle Scholar
  • 83 Aging and Infertility in Women .American Society of Reproductive Medicine (ASRM) Practice Committee Report. http://Available at: www.asrm.org/membersonly/practice/ageandfertility.pdf Accessed January 2002
    Google Scholar

Luis S NobleM.D. 

Associate Clinical Professor, Department of Obstetrics and Gynecology, Texas Tech University Medical Center, Medical Director of Southwest Center for Reproductive Health

El Paso, TX 79912

Email: lsprime@elp.rr.com

      >